About: Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.95 (+1.85%)
NUVB NYSE Nuvation Bio Inc
Nuvation Bio Inc share price
NUVB price activity
Último preço
$ 4,950
Variação (24h)
0,09 USD (1,85%)
Volume
9.29M
Volume (média 4 sem.)
-
Abertura
$ 4,80
Variação do dia
$ 4,63 - $ 4,98
Fechamento anterior
$ 4,86
Último negócio
08 Oct, 8:00 pm GMT+0
Atrasado
08 Oct, 8:00 pm GMT+0
NUVB price performance
Atrasado
08 Oct, 8:00 pm GMT+0
quote.marketSignals